✦ LIBER ✦

A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study

✍ Scribed by Martin, Lainie P.; Sill, Michael; Shahin, Mark S.; Powell, Matthew; DiSilvestro, Paul; Landrum, Lisa M.; Gaillard, Stephanie L.; Goodheart, Michael J.; Hoffman, James; Schilder, Russell J.

Book ID: 121990257
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 246 KB
Volume: 132
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2013.12.018

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II evaluation of motesanib (AMG

A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: A Gynecologic Oncology Group study

✍ Schilder, R.J.; Sill, M.W.; Lankes, H.A.; Gold, M.A.; Mannel, R.S.; Modesitt, S. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 189 KB

A phase II evaluation of mifepristone in

A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: A gynecologic oncology group study

✍ Thomas F. Rocereto; William E. Brady; Mark S. Shahin; James S. Hoffman; Laurie S 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 162 KB

Phase II evaluation of dasatinib in the

Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study

✍ Russell J. Schilder; William E. Brady; Heather A. Lankes; James V. Fiorica; Mark 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 205 KB

A phase II evaluation of lapatinib in th

A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study

✍ Agustin A. Garcia; Michael W. Sill; Heather A. Lankes; Andrew K. Godwin; Robert 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 220 KB

A phase II study of a urokinase-derived

A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: A Gynecologic Oncology Group study

✍ Michael A. Gold; William E. Brady; Heather A. Lankes; Peter G. Rose; Joseph L. K 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 257 KB

A phase II study of vorinostat in the tr

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study

✍ Susan C. Modesitt; Michael Sill; James S. Hoffman; David P. Bender 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 251 KB